NCT05902156Not yet recruiting
Electronic Patient Decision Support System for Patients with Type 2 Diabetes (DiaPaDeSS)
The Effect of Electronic Patient Decision Support System Developed for Use Patients with Type 2 Diabetes (DiaPaDeSS) on Self-Management, Patient Activation and Metabolic Parameters
Source: ClinicalTrials.gov · Last updated 6 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study evaluates the effects of an electronic patient decision support system developed for the use of patients with type 2 diabetes (DiaPaDeSS) on self-management, patient activation, and metabolic parameters. To manage type 2 diabetes after discharge, patients must continue to perform interventions at home, such as blood glucose monitoring, blood pressure measurement, weight measurement, medication use, and foot care. To achieve this, patient's self-management and activation levels should be increased. This can also lead to positive improvements in the metabolic parameters. It would be beneficial to develop DiaPaDeSS that can increase the self-management and activation levels of patients with type 2 diabetes. The investigators will develop the DiaPaDeSS intervention protocol. Our content includes patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), a type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires. The content of the DiaPaDeSS will be evaluated by 10 experts in the fields of medicine, nursing, and informatics. A feasibility test with seven patients will be conducted to evaluate the usability of DiaPaDeSS. A single-blind, randomized controlled trial design will be used. Patients with type 2 diabetes will be pretested and randomized (intervention 36, control 36) to the DiaPaDeSS intervention and control groups. Both the DiaPaDeSS intervention and control groups will use the DiaPaDeSS for three months. While participants in the DiaPaDeSS intervention group can reach all contents of the DiaPaDeSS, others can reach only these fields: self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The effectiveness of the DiaPaDeSS will be evaluated at baseline and at month 3.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- First submitted
- 5 Jun 2023
- Start date
- 30 Mar 2025
- Primary completion date
- 15 Jul 2025
- Lead sponsor
- Akdeniz University
- Diseases
- Type 2 diabetes
- NCT number
- NCT05902156
What you commit to
- Study type: Interventional
- Planned participants: 72
- From 30 Mar 2025 to the primary completion date, 15 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Using steroid therapy
Other illness
- Diagnosed with myocardial infarction, stroke or diabetic foot in the last six months
- Diagnosed with type 1 diabetes or gestational diabetes
- Diagnosed with terminal illness
- Having dementia and cognitive deficits
Other
- Had pregnant
- Having retinopathy or advanced neuropathy
- Patients whose information is not allowed to be accessed
Who the study is looking for
- Patients with type 2 diabetes who had been followed up and treated at the Endocrinology and Metabolic Diseases Polyclinic
- Aged between 18-65 years
- Patients who know their diagnosis and can verbally express it
- Have been diagnosed with type 2 diabetes for at least six months
- Who are literate
- Who have internet access at home, who have one of the tools such as a computer, tablet or smartphone and can use these tools
- Consented to participate in the study
- Had no other psychiatric or mental barriers to answering the questions, language or cognitive difficulties, and barriers to verbal or written communication
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Akdeniz University Coordinator of this site? Confirm its status | Antalya | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.